XOMA Corporation (XOMAO)

Ligand Pharmaceuticals is set to report its second-quarter earnings, which will be the first financial update since its $739 million acquisition of XOMA Royalty Corporation. The report is crucial as analysts expect the deal to be immediately accretive to earnings, with projections of an additional $0.50 per share to 2026 and $1.50 per share to 2027 adjusted earnings. Investors will be closely watching management's commentary on the XOMA integration, the growth of Ligand's expanded royalty portfolio, and future capital deployment plans, especially after the company missed first-quarter estimates.

This article provides an overview of XOMA Royalty Corporation's financial statements and key facts. The company operates as a biotech royalty aggregator, focusing on acquiring future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The article notes that there is currently no market capitalization, revenue, or net income data available, and the company has never paid dividends.

This article provides a detailed financial overview of XOMA Royalty Corp (XOMA), including its income statement, balance sheet, and cash flow statement. It highlights recent earnings, revenue, EPS, and various financial indicators with year-over-year changes across multiple quarters and fiscal years. The content is presented in a data-rich dashboard format to facilitate financial analysis for investors.

XOMA Royalty Corp filed an "EFFECT" form with the SEC, indicating a neutral impact and sentiment. The filing, accepted on July 23, 2026, details an effectiveness date of July 22, 2026, with accession number 0001193125-26-308937. This financial disclosure is part of the company's regular reporting requirements.

XOMA Royalty LLC has filed a post-effective amendment to its Form S-3 shelf registration, originally covering $200 million in various securities, to remove all unsold securities from registration. This action follows a corporate restructuring, where XOMA Royalty Corporation converted to a Delaware limited liability company, and a subsequent merger where it became a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated. All offerings under the shelf registration have been terminated as a result of these changes.